Altimmune (ALT) Return on Capital Employed (2011 - 2026)
Altimmune (ALT) posted quarterly Return on Capital Employed of 32.69% for Q1 2026, up 3821.0% year-over-year from 0.83% in Q1 2025, and up 18.97% quarter-over-quarter from 40.35% in Q4 2025.
Altimmune (ALT) Return on Capital Employed (2011 - 2026) Analysis & Trends
Altimmune (ALT) has reported Return on Capital Employed for 16 consecutive years, with 32.69% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 3821.0% year-over-year to 32.69%; the TTM figure through Mar 2026 stood at 32.69% (up 3821.0% YoY), while the FY2025 annual figure was 48.55%, up 1417.0% from the prior year.
- Return on Capital Employed advanced to 32.69% in Q1 2026 per ALT's latest filing, from 40.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 32.69% in Q1 2026 and bottomed at 77.5% in Q4 2024.
- Historically, Return on Capital Employed has averaged 53.92% across 5 years, with a median of 52.37% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 2712 bps — and 2026, when it soared 3821 bps.
- Altimmune's Return on Capital Employed stood at 44.08% in 2022, then dropped by 23 bps to 54.36% in 2023, then sank by 43 bps to 77.5% in 2024, then soared by 48 bps to 40.35% in 2025, then gained by 19 bps to 32.69% in 2026.
- Business Quant data shows ALT's Return on Capital Employed at 32.69% in Q1 2026, 40.35% in Q4 2025, and 47.17% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | -23.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.92% |
| Mar 31, 2026 | -32.69% |
| Dec 31, 2025 | -40.35% |
| Sep 30, 2025 | -47.17% |
| Jun 30, 2025 | -57.34% |
| Mar 31, 2025 | -70.90% |
| Dec 31, 2024 | -77.50% |
| Sep 30, 2024 | -73.65% |
| Jun 30, 2024 | -66.21% |
| Mar 31, 2024 | -53.66% |
| Dec 31, 2023 | -54.36% |
| Sep 30, 2023 | -52.37% |
| Jun 30, 2023 | -50.42% |
| Mar 31, 2023 | -49.44% |
| Dec 31, 2022 | -44.08% |
| Sep 30, 2022 | -43.91% |
| Jun 30, 2022 | -50.06% |
| Mar 31, 2022 | -52.58% |
| Dec 31, 2021 | -46.24% |
| Sep 30, 2021 | -36.71% |